Results 111 to 120 of about 35,072 (188)

Biological Therapy for Moderate-to-Severe Psoriasis: A 5-Year Analysis of Patients from Lithuania. [PDF]

Medicina (Kaunas)
Indrisiunaite E, Jonaityte IR, Karmaziene T, Raudonis T.   +3 more
europepmc   +1 more source

Acne treated with tumor necrosis factor inhibitors. [PDF]

JAAD Int
Bizuneh LG, Coates SJ, Naik HB, Mathes E, Amerson E.   +4 more
europepmc   +1 more source

Efficacy and safety of dual-targeted therapy with tofacitinib and TNF inhibitors in refractory spondyloarthritis: a case series from a tertiary care center. [PDF]

Ther Adv Musculoskelet Dis
Agrawal A, Yadav SS, Balakrishnan C.
europepmc   +1 more source

Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. [PDF]

Adv Ther
Yamauchi PS, Chow V, Mytych DT, Zhou M, Radziszewski W.   +4 more
europepmc   +1 more source

Case Report: Successful treatment of SAPHO syndrome refractory to adalimumab with upadacitinib. [PDF]

Front Immunol
Du J, Li Y, Geng S, Li C, Shang S.
europepmc   +1 more source

Anti-adalimumab antibodies are associated with loss of response in juvenile idiopathic arthritis. [PDF]

Pediatr Rheumatol Online J
Carrim M, Shipa MRA, Bouraoui A, AlSulaim T, Fisher C, Glanville JRW, Leandro M, Sen D.   +7 more
europepmc   +1 more source

Patient out-of-pocket costs and rheumatology biosimilar competition. [PDF]

J Manag Care Spec Pharm
Dayer VW, Hansen RN, Roth J, Jofre-Bonet M, Sullivan SD.   +4 more
europepmc   +1 more source

Assessment of adalimumab used in a patient with hemorrhagic rheumatoid neutrophilic dermatosis. [PDF]

Postepy Dermatol Alergol
Wei T, Duan Z, Chen H, Xiang Z, Li CR.
europepmc   +1 more source

Biosimilars in Adult and Pediatric Noninfectious Uveitis. [PDF]

Clin Ophthalmol
Ploeger CG, Carvalho Soares Valentim C, Guner ME, Kabaalioglu Guner M.   +3 more
europepmc   +1 more source